Oklo stock tumbles as Financial Times scrutinizes valuation
Merit Medical Systems Inc. (MMSI) stock reached a 52-week low, closing at $79.07. This marks a significant downturn for the medical device company, as its shares have declined by 16.1% over the past year. Despite the decline, the company maintains strong fundamentals with a healthy current ratio of 4.09 and revenue growth of 10.11% in the last twelve months. The stock’s performance reflects broader challenges in the healthcare sector, with investors closely monitoring the company’s strategy to navigate market headwinds. Nine analysts have recently revised their earnings estimates upward, with price targets ranging from $90 to $122. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available in the comprehensive Pro Research Report covering this healthcare leader.
In other recent news, Merit Medical Systems reported strong second-quarter 2025 results, surpassing consensus expectations for both revenue and earnings per share. The company’s organic revenue growth improved to 6.7% year-over-year, an increase from the 6.0% growth reported in the first quarter of 2025. In another development, Merit Medical’s Embosphere Microspheres received European Union approval for use in genicular artery embolization to treat knee osteoarthritis, a procedure that may offer pain relief and improved mobility. Additionally, the company’s SCOUT Radar Localization system has reached a significant milestone, being used in 750,000 patients worldwide for breast cancer treatment.
In leadership changes, Martha G. Aronson was appointed as the new president and CEO of Merit Medical Systems, effective October 3, 2025, following the resignation of Fred P. Lampropoulos. Piper Sandler reaffirmed its Overweight rating on Merit Medical, citing the company’s progress on its Continued Growth Initiatives plan. Needham also maintained a Buy rating on the company, reflecting confidence in its financial performance. These recent developments highlight Merit Medical’s ongoing advancements in medical technology and its strategic leadership transition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.